⌘K

Login Start Free

Home/Filings/4/0001562180-23-007502

4//SEC Filing

Cordova Ashley 4

Accession 0001562180-23-007502

CIK 0001645113other

View on SEC.gov Company Profile

Filed

Nov 1, 8:00 PM ET

Accepted

Nov 2, 4:20 PM ET

Size

18.0 KB

Accession

0001562180-23-007502

Insider Transaction Report

Form 4

Period: 2023-10-31

NovoCure LtdNVCR

Chief Executive Officer

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2023-10-31−2,480→ 0 total
Exercise: $11.44From: 2020-07-27Exp: 2026-07-27→ Ordinary Shares (2,480 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-02−175→ 0 total
Exercise: $11.46Exp: 2026-02-24→ Ordinary Shares (175 underlying)
Exercise/Conversion
Ordinary Shares
2023-10-31$7.15/sh+7,752$55,427→ 117,443 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-10-31−7,561→ 175 total
Exercise: $11.46Exp: 2026-02-24→ Ordinary Shares (7,561 underlying)
Exercise/Conversion
Ordinary Shares
2023-10-31$11.46/sh+7,561$86,649→ 107,211 total
Exercise/Conversion
Ordinary Shares
2023-10-31$11.44/sh+2,480$28,371→ 109,691 total
Exercise/Conversion
Ordinary Shares
2023-11-02$11.46/sh+175$2,006→ 117,618 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-10-31−7,752→ 0 total
Exercise: $7.15Exp: 2027-02-21→ Ordinary Shares (7,752 underlying)

Footnotes (2)

[F1]Vests 2,686 share(s) on 24-Feb-2019, 6,250 share(s) on 24-Feb-2020
[F2]Vests 2 share(s) on 22-Feb-2018, 9,750 share(s) on 22-Feb-2021

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

NovoCure Ltd

CIK 0001645113

Entity typeother

Related Parties

1

filerCIK 0001822014

Filing Metadata

Form type: 4
Filed: Nov 1, 8:00 PM ET
Accepted: Nov 2, 4:20 PM ET
Size: 18.0 KB

View on SEC.gov